Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Determine which funds deliver the best annual risk-adjusted returns and how they stack up. Compare contenders to pick winners.
28,456 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Meta's push into cloud services could reshape AI compute bets. Learn how Nebius and CoreWeave investors might respond...
A market thinker known as the prophet ‘wired belt’ warns that AI-driven shifts are hollowing out knowledge-economy jo...
The allure of a $16 billion contracted revenue pipeline can blind investors to real dangers. This article breaks down...
XRP would need a dramatic rally and strong regulatory clarity to reach $20 this cycle. This report weighs the math, t...
When a chief executive sells a large block of shares, investors understandably take note. This guide breaks down what...
Breaking news: the U.S. says it has hit military targets on Kharg Island in Iran, escalating a regional clash. Market...
A disappointing sale of 7-year notes underscores investor caution as Iran war fears rise. Traders point to a shifting...
A hedge fund recently boosted its position in 10x Genomics, highlighting growing confidence in the biotech tools make...
As the Fed weighs its next move, SoFi stock sits at a crossroads. This guide explains how to think through your optio...
Top AI chiefs urged Congress to curb risks as AI tech makes it easier to design dangerous biological materials. The l...
This in-depth look examines the factors behind wallbox (wbx) 2025 earnings and what they mean for investors. Learn ab...